Triapine®

About Nanopharmaceutics

Nanopharmaceutics is a clinical-stage biotech focused on enhancing drug delivery through nanoparticle formulations, primarily for BCS Class II and IV small molecules. The company has a pipeline of nine clinical-stage programs across oncology, CNS, metabolic, and infectious disease indications, supported by a leadership team with a long track record in product development and government contracting. While privately held, it operates as a subsidiary of the public entity TRON Group Inc. (OTC: TGRP) and leverages affiliate Alchem Laboratories for discovery capabilities, positioning itself to address significant unmet needs in targeted drug delivery.

About Alchem Laboratories

Alchem Laboratories is a long-established, private biotech firm with a dual focus on infectious disease therapeutics and a robust contract development and manufacturing (CDMO) service for clinical-stage APIs. Its core capabilities include custom synthesis, assay development, and high-throughput screening (HTS), supported by leadership with deep experience in drug delivery and government contracting. While its public pipeline data shows activity in oncology and other areas, its stated mission centers on advancing antiviral and antibody treatments, positioning it at the intersection of internal R&D and external service provision.

Therapeutic Areas

Other Cancer Drugs